This effect was reduced by the pan-caspase inhibitor Z-VAD-FMK, consistent with an increased activation of the apoptotic pathway triggered by the up-modulation of TRAIL-R2 and FAS on cytokine-treated BC cells (Fig. 1). The gene discussed is FAS; the disease is breast cancer.